Reduced EIF6 dosage attenuates TP53 activation in models of Shwachman-Diamond syndrome

Usua Oyarbide; Valentino Bezzerri; Morgan Staton; Christian Boni; Arish Shah; Marco Cipolli; Eliezer Calo; Seth J. Corey

doi:10.1172/JCI187778

Reduced EIF6 dosage attenuates TP53 activation in models of Shwachman-Diamond syndrome

Usua Oyarbide,¹ Valentino Bezzerri,² Morgan Staton,¹ Christian Boni,² Arish Shah,³ Marco Cipolli,² Eliezer Calo,³ and Seth J. Corey¹

Published February 18, 2025 - More info

View PDF

Abstract

Shwachman-Diamond syndrome (SDS) is characterized by neutropenia, exocrine pancreatic insufficiency, and bony abnormalities with an increased risk of myeloid neoplasia. Almost all cases of SDS result from biallelic mutations in SBDS. SBDS interacts with EFL1 to displace EIF6 from the 60S ribosomal subunit. Released EIF6 permits the assembly of ribosomal large and small subunits in the cytoplasm. Decreased EIF6 levels due to haploinsufficiency or missense mutations which lead to decreased protein expression may provide a somatic genetic rescue and anti-leukemic effects. We observed accumulation of EIF6 protein in sbds knockout (KO) zebrafish models, confirmed in patient-derived tissues, and correlated with changes in ribosome proteins and TP53 pathways. The mechanism of action for this adaptive response is unknown. To address this, we generated an eif6 zebrafish KO line which do not survive past 10 days post fertilization. We also created two mutants with low Eif6 expression, 5-25% of the wildtype levels, that can survive until adulthood. We bred them with sbds-null strains and analyzed their phenotype and biochemical properties. Low Eif6 levels reduced Tp53 pathway activation but did not rescue neutropenia in Sbds-deficient zebrafish. Further studies elucidating the interplay between SBDS, EIF6, TP53, and cellular stress responses offer promising insights into SDS pathogenesis, somatic genetic rescue, and therapeutic strategies.

Reduced EIF6 dosage attenuates TP53 activation in models of Shwachman-Diamond syndrome

Usua Oyarbide,¹ Valentino Bezzerri,² Morgan Staton,¹ Christian Boni,² Arish Shah,³ Marco Cipolli,² Eliezer Calo,³ and Seth J. Corey¹

Article tools

Metrics

Go to

Reduced EIF6 dosage attenuates TP53 activation in models of Shwachman-Diamond syndrome

Usua Oyarbide,1 Valentino Bezzerri,2 Morgan Staton,1 Christian Boni,2 Arish Shah,3 Marco Cipolli,2 Eliezer Calo,3 and Seth J. Corey1

Article tools

Metrics

Go to

Sign up for email alerts

Usua Oyarbide,¹ Valentino Bezzerri,² Morgan Staton,¹ Christian Boni,² Arish Shah,³ Marco Cipolli,² Eliezer Calo,³ and Seth J. Corey¹